The endocannabinoid system and its therapeutic exploitation
The DOI matches its Crossref record; 160 of the 161 references it cites were found in a registry or an index.
Abstract
The term 'endocannabinoid' - originally coined in the mid-1990s after the discovery of membrane receptors for the psychoactive principle in Cannabis, Delta9-tetrahydrocannabinol and their endogenous ligands - now indicates a whole signalling system that comprises cannabinoid receptors, endogenous ligands and enzymes for ligand biosynthesis and inactivation. This system seems to be involved in an ever-increasing number of pathological conditions. With novel products already being aimed at the pharmaceutical market little more than a decade since the discovery of cannabinoid receptors, the endocannabinoid system seems to hold even more promise for the future development of therapeutic drugs. We explore the conditions under which the potential of targeting the endocannabinoid system might be realized in the years to come.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The obvious implications are that cannabinoids and similarly acting drugs may regulate cognitive functions, modulate food intake, affect both female and male reproduction, provide neuroprotection and be involved in neurodegenerative diseases; pathophysiology of shock; inhibition of fertilized oocyte implantation; inhibition of cancer growth, angiogenesis and metastasis (for a review see ref. 71).”
From Paracetamol: New Vistas of an Old Drug (2006) · cites this paper as [71]
Citations
Cites
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Molecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092 · cited 1×
“∆(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB1 receptor antagonist/inverse agonist SR 141716A Neuropsychopharmacology 24, 198–203 (2001).”
Structure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011 · cited 1×
“The serendipitous cloning in 1990 of the first of such proteins, the CB 1 receptor, came from the screening of an 'orphan' G-protein-coupled receptor (GPCR) with several possible ligand”
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913
Determination and characterization of a cannabinoid receptor in rat brain
Devane, W. A., Dysarz, F. A., Johnson, M. R., Melvin, L. S., & Howlett, A. C. (1988) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09876-1 · Cited by 2,443 · cited 1×
“1 ), led to the identification of plasma membrane CANNABINOID RECEPTORS in 1988 (Ref”
Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish
Gaoni, Y., & Mechoulam, R. (1964) · Journal of the American Chemical Society · doi:10.1021/ja01062a046 · Cited by 2,393
2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2437 · Cited by 2,196
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., & Gilula, N. B. (1996) · Nature · doi:10.1038/384083a0 · Cited by 2,125
The molecular logic of endocannabinoid signalling
Piomelli, D. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1247 · Cited by 1,957 · cited 1×
“Functions of the endocannabinoid system The components ( Figs 3 , 4 ) and possible physiological functions of the endocannabinoid system have been extensively reviewed in recent article”
SR141716A, a potent and selective antagonist of the brain cannabinoid receptor
Rinaldi-Carmona, M., Barth, F., Héaulme, M., Shire, D., Calandra, B., Congy, C., Martinez, S., Maruani, J., Néliat, G., Caput, D., et al. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00773-x · Cited by 1,757
Research works printed but not linked: 4
- Mechoulam, R. in Cannabis as Therapeutic Agent (ed. Mechoulam, R.) 1–19 (CRC Press Roca Ranton, 1986). The most comprehensive history of the recreational and medicinal use of Cannabis throughout the centuries.
- Di Marzo, V., Bisogno, T., De Petrocellis, L., Berger, A. & Mechoulam, R. in Biology of Marijuana (ed. Onaivi, E.) 125–173 (Harwood Academic, Reading, 2002).
- Pertwee, R. G. in Cannabinoids (ed. Di Marzo, V.) 32–83 (Kluwer Academic, New York, 2004).
- Pop, E. Dexanabinol Pharmos. Curr. Opin. Investig. Drugs 1, 494–503 (2000).
Cited by
Items 201–300 of 1,001
p38 MAPK is involved in CB2 receptor‐induced apoptosis of human leukaemia cells
Herrera, B., Carracedo, A., Diez-Zaera, M., Guzmán, M., & Velasco, G. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.08.021 · Cited by 79
“pounds [8,9].”
A Covering Method for Detecting Genetic Associations between Rare Variants and Common Phenotypes
Bhatia, G., Bansal, V., Harismendy, O., Schork, N. J., Topol, E. J., Frazer, K., & Bafna, V. (2010) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000954 · Cited by 87
“The endocannabinoid pathway is an important mediator of a variety of neurological functions [18,19].”
BackgroundO'Connell, T. J., & Bou-Matar, C. B. (2007) · Harm Reduction Journal · doi:10.1186/1477-7517-4-16 · Cited by 84
“That notion is further supported by recent literature indicating that phytocannabinoids, newly discovered endocannabinoids, and synthetic cannabinoid agonists all seem to manifest anxiolytic effects in both humans and animals [4-8].”
Blood–Brain Barrier Pathophysiology following Traumatic Brain Injury
Price, L. I., Wilson, C., & Grant, G. A. (2015) · Frontiers in neuroscience · doi:10.1201/b18959-5 · Cited by 93
Matias, I., Wang, J. W., Moriello, A. S., Nieves, A., Woodward, D. F., & Di Marzo, V. (2006) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2006.08.002 · Cited by 89
“We, therefore, hypothesized that, like in other tissues and organs [41], changes in endocannabinoid levels are related to the occurrence and development of a certain disease also in ocular tissues.”
BackgroundSelf-citationSang, N., Zhang, J., & Chen, C. (2006) · The Journal of Physiology · doi:10.1113/jphysiol.2006.105569 · Cited by 89
“Endocannabinoids are involved in a variety of physiological and pathological processes in mammalian tissue via CB1 and CB2 receptors (Hajos & Freund, 2002a; Freund et al. 2003; Piomelli, 2003; Alger, 2004; Howlett et al. 2004; Di Marzo et al. 2004; Patrignani et al. 2005).”
BackgroundEffect fingerprinting of new psychoactive substances (NPS): What can we learn from in vitro data?
Hondebrink, L., Zwartsen, A., & Westerink, R. H. S. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.10.022 · Cited by 80
“CB1 receptors are amongst the most abundant GPCRs in the central nervous system, although they are also present in the peripheral nervous system (Di Marzo, Bifulco, & Petrocellis, 2004).”
Weight-Reducing Side Effects of the Antiepileptic Agents Topiramate and Zonisamide
Antel, J., & Hebebrand, J. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-24716-3_20 · Cited by 89
de Lago, E., Petrosino, S., Valenti, M., Morera, E., Ortega‐Gutiérrez, S., Fernández‐Ruíz, J., & Marzo, V. D. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.05.011 · Cited by 89
Self-citationPalazzo, E., De Novellis, V., Petrosino, S., Marabese, I., Vita, D., Giordano, C., Di Marzo, V., Mangoni, G. S., Rossi, F., & Maione, S. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.05086.x · Cited by 86
Self-citationEnvironmental factors as disease accelerators during chronic hepatitis C
Mallat, A., Hézode, C., & Lotersztajn, S. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.01.004 · Cited by 86
“[62,63].”
Pacher, P., Bátkai, S., Osei-Hyiaman, D., Offertáler, L., Liu, J., Harvey-White, J., Brassai, A., Járai, Z., Cravatt, B. F., & Kunos, G. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00107.2005 · Cited by 79
“This selectivity in the appearance of an endocannabinergic tone for some but not other cannabinoid-regulated behaviors suggests that FAAH may represent an attractive therapeutic target for treating pain and related neurological disorders, as well as anxiety, without the abuse potential of direct acting CB1 agonists (1…”
BackgroundLaricchiuta, D., & Petrosini, L. (2014) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2014.00238 · Cited by 84
“Endocannabinoid system and dopaminergic system dynamically interact in controlling neuronal, endocrine, and metabolic responses to reward (Di Marzo et al., 2004; Fernández-Ruiz et al., 2010).”
BackgroundCNS-targets in control of energy and glucose homeostasis
Kleinridders, A., Könner, A. C., & Brüning, J. C. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.10.006 · Cited by 84
Cannabis Use and Obesity and Young Adults
Hayatbakhsh, M. R., O'Callaghan, M. J., Mamun, A. A., Williams, G. M., Clavarino, A. M., & Najman, J. M. (2010) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2010.500438 · Cited by 84
“Though clinical and laboratory research has revealed the role of the cannabinoid-1 receptor in the regulation of energy balance and body composition (15), population-based data on”
BackgroundMcQuade, D., Hudson, S. C., Dargan, P. I., & Wood, D. M. (2012) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1379-2 · Cited by 83
Walczak, J., Price, T. J., & Cerveró, F. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2009.01.050 · Cited by 83
“The localization of CB1 receptors in nerve fibers located in the suburothelial layer of the bladder wall, and therefore putative afferent fibers, could be the substrate for the effects observed in the electrophysiological experiments as it is known that activation of CB1 receptors can reduce neuronal activity ( Di Mar…”
BackgroundThe Endocannabinoid Noladin Ether Acts as a Full Agonist at Human CB2 Cannabinoid Receptors
Shoemaker, J. L., Joseph, B. K., Ruckle, M. B., Mayeux, P. R., & Prather, P. L. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.085282 · Cited by 83
“The general consensus is that cannabinoids are initially protective, but continuous activation leads to negative events (Di Marzo et al., 2004). at A SPE T Journals on A ugust 20, 2017 jpet.aspetjournals.org D ow nloaded from JPET #85282 19 Many studies indicate that chronic exposure to…”
BackgroundTherapeutic applications of cannabinoids
Maurya, N., & Velmurugan, B. K. (2018) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2018.07.018 · Cited by 83
Aquila, S., Guido, C., Santoro, A., Perrotta, I. D., Laezza, C., Bifulco, M., & Andò, S. (2010) · The Anatomical Record · doi:10.1002/ar.21042 · Cited by 82
“The signaling pathways through which ECs induce apoptosis is under active investigation and may vary based on cell type (Dobrosi et al., 2008; Turco et al., 2008).”
BackgroundSelf-citationDistribution and function of monoacylglycerol lipase in the gastrointestinal tract
Duncan, M., Thomas, A. D., Cluny, N. L., Patel, A., Patel, K. D., Lutz, B., Piomelli, D., Alexander, S. P. H., & Sharkey, K. A. (2008) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.90500.2008 · Cited by 82
“CANNABINOID (CB) receptors (termed CB1 and CB2), the endogenous ligands for these receptors (endocannabinoids), and their biosynthetic and catabolic enzymes form the endocannabinoid system (11, 12).”
Chemical and Physical Elicitation for Enhanced Cannabinoid Production in Cannabis
Gorelick, J., & Bernstein, N. (2017) · Springer eBooks · doi:10.1007/978-3-319-54564-6_21 · Cited by 82
Griebel, G., Stemmelin, J., Lopez‐Grancha, M., Fauchey, V., Slowinski, F., Pichat, P., Dargazanli, G., Abouabdellah, A., Cohen, C., & Bergis, O. E. (2018) · Scientific Reports · doi:10.1038/s41598-018-20895-z · Cited by 82
Pasquini, S., Botta, L., Semeraro, T., Mugnaini, C., Ligresti, A., Palazzo, E., Maione, S., Marzo, V. D., & Corelli, F. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800552f · Cited by 80
Self-citationFerreira-Vieira, T. H., Bastos, C. P., Pereira, G. S., Moreira, F. A., & Massensini, A. R. (2014) · Hippocampus · doi:10.1002/hipo.22206 · Cited by 69
Siegmund, S., & Schwabe, R. F. (2007) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00456.2007 · Cited by 80
“Shortly after the cloning of these receptors, mediators were discovered that serve as endogenous ligands for these receptors and were termed endocannabinoids (9).”
BackgroundEndocannabinoid System and Exogenous Cannabinoids in Depression and Anxiety: A Review
Hasbi, A., Madras, B. K., & George, S. R. (2023) · Brain Sciences · doi:10.3390/brainsci13020325 · Cited by 79
A Rapid Response Electrochemical Biosensor for Detecting Thc In Saliva
Stevenson, H., Bacon, A., Joseph, K. M., Gwandaru, W. R. W., Bhide, A., Sankhala, D., Dhamu, V. N., & Prasad, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-49185-y · Cited by 79
Bari, M., Spagnuolo, P., Fezza, F., Oddi, S., Pasquariello, N., Finazzi‐Agrò, A., & Maccarrone, M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.8.4971 · Cited by 77
“These include food intake, cancer, and immune suppression (22, 67, 68).”
BackgroundRimonabant: Just an Antiobesity Drug? Current Evidence on Its Pleiotropic Effects
Bifulco, M., Grimaldi, C., Gazzerro, P., Pisanti, S., & Santoro, A. (2007) · Molecular Pharmacology · doi:10.1124/mol.106.033118 · Cited by 77
“…restricted CB2), five endogenous lipid-like ligands [including the well known endocannabinoids anandamide (AEA) and 2-arachidonoyl glycerol], and the enzymes involved in their biosynthesis and degradation (for review, see Mechoulam et al., 1998; De Petrocellis et al., 2004; Di Marzo et al., 2004).”
BackgroundSelf-citationMedical marijuana users in substance abuse treatment
Swartz, R. (2010) · Harm Reduction Journal · doi:10.1186/1477-7517-7-3 · Cited by 76
“Marijuana has already shown therapeutic potential for anxiety symptoms [10].”
BackgroundEndocannabinoids and liver disease† ‡
Jiménez, W. (2005) · Hepatology · doi:10.1002/hep.20714 · Cited by 74
Roche, M., Diamond, M., Kelly, J. P., & Finn, D. P. (2006) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.08.001 · Cited by 76
“…(Δ9THC), the main psychoactive constituent of marijuana, and related analogues, modulate a range of physiological processes including appetite, memory, mood, cardiovascular system, pain and immune function (Di Marzo et al., 2004; Finn and Chapman, 2004; Grotenhermen, 2005; Klein, 2005).”
BackgroundNicolussi, S., Paredes, J. M. V., Gachet, M. S., Rau, M., Flores-Soto, M. E., Blunder, M., & Gertsch, J. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2013.12.010 · Cited by 76
“The endocannabinoid system (ECS) is a lipid signaling sysem comprising endocannabinoids (ECs), which are lipids derived rom arachidonic acid, the G-protein-coupled cannabinoid recepors CB1 and CB2, as well as several other actual and potential hysiological targets involved in the synthesis, transport and egradation of…”
BackgroundBlaazer, A. R., Lange, J. H. M., van der Neut, M. A. W., Mulder, A. T., den Boon, F. S., Werkman, T. R., Kruse, C. G., & Wadman, W. J. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.08.021 · Cited by 76
Mazzoccanti, G., Ismail, O. H., D’Acquarica, I., Villani, C., Manzo, C., Wilcox, M., Cavazzini, A., & Gasparrini, F. (2017) · Chemical Communications · doi:10.1039/c7cc06999e · Cited by 76
Laere, K. V., Goffin, K. E., Bormans, G. M., Casteels, C., Mortelmans, L., Hoon, J. N. J. M. D., Grachev, I. D., Vandenbulcke, M., & Pieters, G. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2008.530 · Cited by 75
“Since the discovery of endogenous cannabinoids in the early 1990s, considerable interest in the endocannabinoid system has arisen.(9,10) Experimental studies in animals and observational studies on the effects of cannabis in humans have implied important functions for the endocannabinoid system in cognitive, motor, re…”
BackgroundYan, W., Cao, Y., Yang, H., Han, N., Zhu, X., Fan, Z., Du, J., & Zhang, F. (2019) · Cell Proliferation · doi:10.1111/cpr.12691 · Cited by 75
Intestinal Monoacylglycerol Metabolism
Chon, S., Zhou, Y. X., Dixon, J. L., & Storch, J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m706994200 · Cited by 74
Interactions between the cannabinoid and dopaminergic systems: Evidence from animal studies
Khoury, M. E., Gorgievski, V., Moutsimilli, L., Giros, B., & Tzavara, E. T. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.12.005 · Cited by 73
The endocannabinoid system: Role in glucose and energy metabolism
Nogueiras, R., Díaz–Arteaga, A., Lockie, S. H., Velasquez, D., Tschöp, J., López, M., Cadwell, C. C., Diéguez, C., & Tschöp, M. H. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.04.004 · Cited by 73
Adamczyk, P., McCreary, A. C., Przegaliński, E., Mierzejewski, P., Bieńkowski, P., & Filip, M. (2009) · PubMed · Cited by 73
Youssif, B. G. M., Mohamed, A. M., Osman, E. E. A., Abou‐Ghadir, O. F., Elnaggar, D. H., Abdelrahman, M. H., Treamblu, L., & Gomaa, H. A. M. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.040 · Cited by 73
Safety Considerations in Cannabinoid-Based Medicine
Gottschling, S., Ayonrinde, O., Bhaskar, A., Blockman, M., D’Agnone, O., Schecter, D., Rodríguez, L. D. S., Yafai, S., & Cyr, C. (2020) · International Journal of General Medicine · doi:10.2147/ijgm.s275049 · Cited by 73
Paraskeva (2010) · International Journal of Oncology · doi:10.3892/ijo_00000666 · Cited by 73
Galdino, G., Romero, T., Pinho da Silva, J. F., Aguiar, D., de Paula, A. M., Cruz, J., Parrella, C., Piscitelli, F., Duarte, I., Di Marzo, V., et al. (2014) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000000340 · Cited by 72
Self-citationCannabis Use Does Not Affect Outcomes After Total Knee Arthroplasty
Jennings, J. M., Angerame, M. R., Eschen, C. L., Phocas, A. J., & Dennis, D. A. (2019) · The Journal of Arthroplasty · doi:10.1016/j.arth.2019.04.015 · Cited by 72
Therapeutic properties of multi-cannabinoid treatment strategies for Alzheimer’s disease
Coles, M., Steiner-Lim, G. Z., & Karl, T. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.962922 · Cited by 72
Schwitzer, T., Schwan, R., Angioï-Duprez, K., Ingster-Moati, I., Lalanne, L., Giersch, A., & Laprévote, V. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.11.002 · Cited by 72
Lysophosphatidylinositol Causes Neurite Retraction via GPR55, G13 and RhoA in PC12 Cells
Obara, Y., Ueno, S., Yanagihata, Y., & Nakahata, N. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024284 · Cited by 72
“Cannabinoids, which include the bioactive constituents of the marijuana plant Cannabis sativa and its synthetic or endogenous counterparts, modulate a range of central nervous system functions, and affect peripheral sites, such as immune function and the cardiovascular system [1,2].”
BackgroundReview Paper: Current Strategies in the Development of Anti-obesity Drugs and Their Safety Concerns
Elangbam, C. S. (2009) · Veterinary Pathology · doi:10.1354/vp.46-1-10 · Cited by 66
Turgeman, I., & Bar‐Sela, G. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1561859 · Cited by 72
“mitogen-activated protein kinases, and CB1 receptors are also known to modulate calcium and potassium channels [10].”
BackgroundSilvestri, R., Cascio, M. G., Regina, G. L., Piscitelli, F., Lavecchia, A., Brizzi, A., Pasquini, S., Botta, M., Novellino, E., Marzo, V. D., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm070566z · Cited by 72
Self-citationCoopman, K., Smith, L. D., Wright, K. L., & Ward, S. G. (2006) · International Immunopharmacology · doi:10.1016/j.intimp.2006.11.008 · Cited by 72
Antitumorigenic effects of cannabinoids beyond apoptosis.
Freimuth, N., Ramer, R., & Hinz, B. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.157735 · Cited by 71
Cannabinoid use and self-injurious behaviours: A systematic review and meta-analysis
Escelsior, A., Murri, M. B., Corsini, G. P., Serafini, G., Aguglia, A., Zampogna, D., Cattedra, S., Nebbia, J., Trabucco, A., Prestía, D., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.09.020 · Cited by 71
Gamaleddin, I., Zvonok, A. M., Makriyannis, A., Goldberg, S. R., & Foll, B. L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029900 · Cited by 71
“The cannabinoid system consists of CB1 and CB2 receptors, the endogenous cannabinoid receptor ligands, anandamide, and 2-arachidonoylglycerol (2-AG) [2,3], in addition to the enzymes responsible for their degradation which are fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase 2-AG, respectively [2,4].”
BackgroundA Population-Based Case-Control Study of Marijuana Use and Head and Neck Squamous Cell Carcinoma
Liang, C., McClean, M. D., Marsit, C. J., Christensen, B. C., Peters, E. S., Nelson, H. H., & Kelsey, K. T. (2009) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-09-0048 · Cited by 71
“Further, additional work shows that cannabinoids are potent anti-inflammatory agents (10, 11).”
BackgroundIndole-2-carboxamides as Allosteric Modulators of the Cannabinoid CB1 Receptor
Piscitelli, F., Ligresti, A., Regina, G. L., Coluccia, A., Morera, L., Allarà, M., Novellino, E., Marzo, V. D., & Silvestri, R. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201485c · Cited by 71
Self-citationHeyman, E., Gamelin, F.-X., Aucouturier, J., & Marzo, V. D. (2012) · Obesity Reviews · doi:10.1111/j.1467-789x.2012.01026.x · Cited by 71
“While CB2 receptors are predominantly involved in inflammation and immune processes (9), CB1 receptors, which are expressed in central as well as peripheral tissues, have been shown to influence glucose and lipid metabolic pathways (3,10,11) as well as multiple behaviours including food intake also through the modulat…”
BackgroundSelf-citationGustafsson, K., Wang, X., Severa, D., Eriksson, M., Kimby, E., Merup, M., Christensson, B., Flygare, J., & Sander, B. (2008) · International Journal of Cancer · doi:10.1002/ijc.23584 · Cited by 66
“They have properties similar to compounds of Cannabis sativa and have recently been shown to have effects on various types of cancer.(9) Many of the effects of natural and synthetic cannabinoids are mediated through the cannabinoid receptors.”
BackgroundReux, B., Nevalainen, T., Raitio, K. H., & Koskinen, A. M. P. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.05.013 · Cited by 70
Novel 3,4-diarylpyrazolines as potent cannabinoid CB1 receptor antagonists with lower lipophilicity
Lange, J. H. M., van Stuivenberg, H. H., Veerman, W., Wals, H. C., Stork, B., Coolen, H. K. A. C., McCreary, A. C., Adolfs, T. J. P., & Kruse, C. G. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.07.054 · Cited by 70
Ligresti, A., Cascio, M. G., Pryce, G., Kulasegram, S., Beletskaya, I., De Petrocellis, L., Saha, B., Mahadevan, A., Visintin, C., Wiley, J. L., et al. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706418 · Cited by 65
“…‘central’ cannabimimetic activity (as assessed here in the mouse ‘tetrad’ of tests), O-3246 and O-3262 can serve as templates for the development of a new generation of potent endocannabinoid uptake inhibitors with several potential therapeutic applications (see Di Marzo et al., 2004a for review).”
BackgroundInfluentialSelf-citationEndocannabinoids in endocrine and related tumours.
Bifulco, M., Malfitano, A., Pisanti, S., & Laezza, C. (2008) · Endocrine-Related Cancer · doi:10.1677/erc-07-0258 · Cited by 71
Self-citationMukerji, G., Yiangou, Y., Agarwal, S. K., & Anand, P. (2010) · Urology · doi:10.1016/j.urology.2009.12.051 · Cited by 69
Scheen, A. J. (2008) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2008.01681.x · Cited by 68
Dudek, K., Paton, S. E. J., Binder, L. B., Collignon, A., Dion‐Albert, L., Cadoret, A., Lebel, M., Lavoie, O., Bouchard, J., Kaufmann, F. N., et al. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-01891-9 · Cited by 68
“Cannabinoid receptor 1 (CB1, encoded by Cnr1 ) is the main ECS effector in the brain, and CB1 downstream signaling has been implicated in stress resilience 10,11 .”
Self-citationVincenzi, F., Targa, M., Corciulo, C., Tabrizi, M. A., Merighi, S., Gessi, S., Saponaro, G., Baraldi, P. G., Borea, P. A., & Varani, K. (2013) · Pain · doi:10.1016/j.pain.2013.02.007 · Cited by 62
“CB1 receptors are expressed at high levels in the central nervous system (CNS) and their activation results in hypothermia, sedation, catalepsy, and altered mental status [20,44].”
BackgroundTargeting the cannabinoid system for pain relief?
Chiou, L., Hu, S. S., & Ho, Y. (2013) · Acta anaesthesiologica Taiwanica · doi:10.1016/j.aat.2013.10.004 · Cited by 68
Boyd, S. T. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.12part2.218s · Cited by 68
“The various locations of CB1 receptors are important to recognize because certain metabolic consequences can occur if the endocannabinoid system becomes overactive.(5) Table 1 summarizes the effects of the endocannabinoid system on metabolic parameters and energy balance.”
BackgroundCannabinoids in the Modulation of Oxidative Signaling
Pagano, C., Savarese, B., Coppola, L., Navarra, G., Avilia, G., Laezza, C., & Bifulco, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032513 · Cited by 67
“The distribution of CB1 and CB2 receptors is well described and accounts for the recognized psychotropic and peripheral effects of THC: CB1 is highly abundant in the central nervous system (CNS) and in the peripheral nervous system (PNS), while the presence of CB2 receptors is predominantly restricted to immune tissue…”
BackgroundSelf-citationHunger and thirst: Issues in measurement and prediction of eating and drinking
Mattes, R. D. (2010) · Physiology & Behavior · doi:10.1016/j.physbeh.2009.12.026 · Cited by 68
“Although there is an acute leptin response to meals, concentrations are directly related to body fat stores [56].”
Carbamoyl tetrazoles as inhibitors of endocannabinoid inactivation: A critical revisitation
Ortar, G., Cascio, M. G., Moriello, A. S., Camalli, M., Morera, E., Nalli, M., & Marzo, V. D. (2007) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2007.02.023 · Cited by 67
Self-citationVlachou, S., & Panagis, G. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990433 · Cited by 67
“This system consists of cannabinoid (CB) receptors (CB1, CB2, and possibly others), endogenous ligands for these receptors and enzymes/proteins responsible for the synthesis, reuptake and degradation of these endogenous ligands [15-17].”
BackgroundFowler, C. J. (2006) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.2006.00442.x · Cited by 57
Cannabinoid receptors as new targets of antifibrosing strategies during chronic liver diseases
Mallat, A., Teixeira-Clerc, F., Deveaux, V., & Lotersztajn, S. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.3.403 · Cited by 62
“Identification of specific receptors for plant-derived cannabinoids was followed by the characterization of endocannabinoids, a growing family of endogenous arachidonic acid-derived ligands (for reviews see [4,5]).”
BackgroundPasquale, E. D., Chahinian, H., Sanchez, P., & Fantini, J. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004989 · Cited by 66
Kerr, D. M., Burke, N. N., Ford, G. K., Connor, T., Harhen, B., Egan, L. J., Finn, D. P., & Roche, M. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.09.032 · Cited by 66
“As such, endocannabinoid regulation of immune function represents an important therapeutic target for a number of peripheral and central inflammatory disorders (Di Marzo et al., 2004; Baker et al., 2007; Centonze et al., 2007; Finn, 2009; Orgado et al., 2009).”
Involvement of the endocannabinoid system in osteoarthritis pain
Porta, C. L., Bura, S. A., Negrete, R., & Maldonado, R. J. (2014) · European Journal of Neuroscience · doi:10.1111/ejn.12468 · Cited by 66
Messalli, E., Grauso, F., Luise, R., Angelini, A., & Rossiello, R. (2014) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2014.04.004 · Cited by 59
The effects of cannabidiol on male reproductive system: A literature review
de Carvalho, R. K., Andersen, M. L., & Mazaro‐Costa, R. (2019) · Journal of Applied Toxicology · doi:10.1002/jat.3831 · Cited by 66
Garai, S., Kulkarni, P. M., Schaffer, P. C., Leo, L. M., Brandt, A. L., Zagzoog, A., Black, T., Lin, X., Hurst, D. P., Janero, D. R., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01142 · Cited by 66
Novel therapeutic targets for enteric nervous system disorders
DEGIORGIO, R., BARBARA, G., FURNESS, J., & TONINI, M. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.08.003 · Cited by 60
Milloy, M., Marshall, B. D. L., Kerr, T. H., Richardson, L., Hogg, R. S., Guillemi, S. A., Montaner, J. S. G., & Wood, E. (2014) · Drug and Alcohol Review · doi:10.1111/dar.12223 · Cited by 65
Zuo, L., Kranzler, H. R., Luο, X., Yang, B., Weiss, R. D., Brady, K. T., Poling, J. C., Farrer, L. A., & Gelernter, J. E. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.206 · Cited by 64
“…of the most abundant neuromodulators in the mammalian brain, including neocortex, hippocampus, basal ganglia, cerebellum, striatum, and the ventral tegmental area (VTA) (Arnold 2005; Di Marzo et al 2004; Herkenham et al 1990; Mailleux and Vanderhaeghen 1992; Solinas et al 2008; Tsou et al 1998).”
BackgroundColes, M., Watt, G., Kreilaus, F., & Karl, T. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.587604 · Cited by 64
“A recent approach in the race for the treatment for AD involves targeting the endocannabinoid system, which is involved in numerous basic functions of the human body (Di Marzo et al., 2004; Benito et al., 2007), and testing constituents of the cannabis sativa plant (i.e., phytocannabinoids).”
BackgroundCannabinoid receptors and pain
Starowicz, K., Małek, N., & Przewłocka, B. (2013) · Wiley Interdisciplinary Reviews Membrane Transport and Signalling · doi:10.1002/wmts.83 · Cited by 63
Shouman, B., Fontaine, R. H., Baud, O., Schwendimann, L., Keller, M., Spedding, M., Lelièvre, V., & Gressèns, P. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706755 · Cited by 63
“…of Pharmacology (2006) 148, 442–451. doi:10.1038/sj.bjp.0706755; published online 8 May 2006 Keywords: Anandamide; CB1 receptor; cerebral palsy; neuroprotection; NMDA; oligodendrocyte; periventricular leukomalacia; willardiine Abbreviations: ACPA, arachidonylcyclopropylamide; CP, cerebral palsy”
BackgroundInfluentialImplications of Altered Gastrointestinal Motility in Obesity
Gallagher, T. K., Geoghegan, J., Baird, A. W., & Winter, D. C. (2007) · Obesity Surgery · doi:10.1007/s11695-007-9221-0 · Cited by 63
Role of Cannabinoids in Gastrointestinal Mucosal Defense and Inflammation
Gyires, K., & Zádori, Z. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666160303110150 · Cited by 62
“These lipid mediators are not stored but synthesized on demand in a site- and time-dependent manner and are rapidly degraded after exerting a transient and localized effect [8].”
Oddi, S., Bari, M., Battista, N., Barsacchi, D., Cozzani, I., & Maccarrone, M. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4446-8 · Cited by 62
Cannabis for Medical Use: Versatile Plant Rather Than a Single Drug
Procaccia, S., Lewitus, G. M., Feder, C. L., Shapira, A., Berman, P., & Meiri, D. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.894960 · Cited by 61
Wang, L., Mori, W., Cheng, R., Yui, J., Hatori, A., Ma, L., Zhang, Y., Rotstein, B. H., Fujinaga, M., Shimoda, Y., et al. (2016) · Theranostics · doi:10.7150/thno.15257 · Cited by 61
“of which have led to continued efforts in the search of eCB-targeting drugs to modulate these conditions.[5, 6] Since direct stimulation of CB1 receptors is generally accompanied by undesirable side effects,[7] drug discovery has focused on alteration of 2-AG and/or AEA metabolism, through inhibiting the functions of…”
BackgroundBiosynthesis and Fate of Endocannabinoids
Cascio, M. G., & Marini, P. (2015) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-20825-1_2 · Cited by 60
Sarott, R. C., Viray, A. E. G., Pfaff, P., Sadybekov, A., Rajic, G., Katritch, V., Carreira, E. M., & Frank, J. A. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.0c08926 · Cited by 60
Biological specificity of visceral adipose tissue and therapeutic intervention
Perrini, S., Leonardini, A., Laviola, L., & Giorgino, F. (2008) · Archives of Physiology and Biochemistry · doi:10.1080/13813450802334752 · Cited by 60
“The two cannabinoid receptors identified to date, CB1 and CB2, are G-protein coupled receptors (Pagotto et al., 2006a; Di Marzo et al., 2004).”
BackgroundEffects of chronic nicotine on food intake and anxiety-like behaviour in CB1 knockout mice
Bura, S. A., Burokas, A., Martín‐García, E., & Maldonado, R. J. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.02.003 · Cited by 60
“In the hypothalamus, CB1 receptor activation enhances appetite ts reserved. by regulating the responses of several orexigenic and anorectic mediators (Di Marzo et al., 2004; Di Marzo and Matias, 2005; Osei-Hyiamanet al., 2005; Kirkham, 2005).”
Manera, C., Saccomanni, G., Malfitano, A. M., Bertini, S., Castelli, F., Laezza, C., Ligresti, A., Lucchesi, V., Tuccinardi, T., Rizzolio, F., et al. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.03.031 · Cited by 59
Self-citationPastuhov, S. I., Fujiki, K., Nix, P., Kanao, S., Bastiani, M. J., Matsumoto, K., & Hisamoto, N. (2012) · Nature Communications · doi:10.1038/ncomms2136 · Cited by 59
Metadata
- Authors
- Marzo, V. D., Bifulco, M., & Petrocellis, L. D.
- Affiliations
- Istituto di Chimica Biomolecolare (IT)
- Institute of Applied Science and Intelligent Systems (IT)
- University of Salerno (IT)
- Corresponding author
- Marzo, Vincenzo Di
- Venue
- Nature Reviews Drug Discovery
- Published
- 2004-09-01
- Volume
- 3
- Issue
- 9
- Pages
- 771-784
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2087674201
- Cited by
- 1,090
- References
- 161
- Citations by year
- 2026: 25 · 2025: 38 · 2024: 61 · 2023: 48 · 2022: 43 · 2021: 44 · 2020: 49 · 2019: 43 · 2018: 35 · 2017: 41 · 2016: 28 · 2015: 42 · 2014: 38 · 2013: 48 · 2012: 42
- FWCI
- 8.47
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- endocannabinoid system, cannabinoid receptors, cannabinoid therapeutics, drug development, pathological conditions
- MeSH terms
- Animals, Cannabinoids, Cannabis, Clinical Trials as Topic, Enzymes, Humans, Drug Design, Signal Transduction, Receptors, Cannabinoid, Cannabinoid Receptor Modulators, Cannabinoid Receptor Agonists, Cannabinoid Receptor Antagonists, Endocannabinoids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.